Termination of collaboration agreement with Ono Pharmaceutical

Current report no. 19/2025

Drafting date: 17.04.2025

Subject: Termination of collaboration agreement with Ono Pharmaceutical

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A., based in Wrocław, Poland (the ‘Company’) informs that today, the Company received from Ono Pharmaceutical Co., Ltd. (‘Ono’) decision on termination of collaboration agreement concluded between the Company and Ono on 14 November 2022 (‘Agreement’) (the Company informed on conclusion of the agreement by current report 40/2022 dated 14 November 2022). In accordance with provisions of the Agreement, the Agreement will expire in 60 days.

Both the Company and Ono are satisfied with the collaboration. In the course of collaboration active molecules were identified– the rights to lead compounds will belong to the Company in accordance with the Agreement. The Company does not exclude that, in the right time, it may consider their further development.

At the same time, the Company maintains the information presented in the 2024 annual report that the Company currently has secured financial resources to operate until the end of the second quarter of 2026.